Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis

Brain

Volumn 126, Issue 8, 2003, Pages 1895-1904

  Schmidt, Jens ^a,c   Metselaar, Josbert M ^b   Wauben, Marca H M ^b   Toyka, Klaus V ^a   Storm, Gert ^b   Gold, Ralf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Autoimmunity; Experimental autoimmune encephalomyelitis; Glucocorticosteroid pulse therapy; Long circulating steroid liposomes; Neuroinflammatory diseases

Indexed keywords

BUFA; GLUCOCORTICOID; LIPOSOME; MACROGOL; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISOLONE 21 PHOSPHATE; PREDNISOLONE DERIVATIVE; PREDNISOLONE LIPOSOME; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG LABELING; DRUG MEGADOSE; DRUG TARGETING; FEMALE; GLIA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNIZATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RELAPSE;

EID: 0043268760     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg176     Document Type: Article

References (32)

1. Amselem S, Gabizon A, Barenholz Y. A large-scale method for the preparation of sterile and non-pyrogenic liposomal formulations of defined size distributions for clinical use. In: Gregoriadis G, editor. Liposome technology. 2nd edn. Boca Raton (FL): CRC Press; 1993. p. 501-25.
2. Brann DW, Hendry LB, Mahesh VB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol 1995; 52: 113-33.
3. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247: 435-42.
4. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41: 761-7.
5. Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, et al. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000; 41: 622-30.
6. de Silva M, Hazleman BL, Thomas DP, Wraight P. Liposomes in arthritis: a new approach. Lancet 1979; 1: 1320-2.
7. Dingle JT, Gordon JL, Hazleman BL, Knight CG, Page Thomas DP, Phillips NC, et al. Novel treatment for joint inflammation. Nature 1978; 271: 372-3.
8. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-92.
9. Gold R, Schmied M, Giegerich G, Breitschopf H, Hartung HP, Toyka KV, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994; 71: 219-25.
10. Gold R, Giegerich G, Hartung HP, Toyka KV. T-cell receptor (TCR) usage in Lewis rat experimental autoimmune encephalomyelitis: TCR beta-chain-variable-region V beta 8.2-positive T cells are not essential for induction and course of disease. Proc Natl Acad Sci USA 1995; 92: 5850-4.
11. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol 2001; 117: 1-8.
12. Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001; 91: 1826-33.
13. Huang SK, Hong K, Lee KD, Papahadjopoulos D, Friend DS. Light microscopic localization of silver-enhanced liposome-entrapped colloidal gold in mouse tissues. Biochim Biophys Acta 1991; 1069: 117-21.
14. Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 1990; 172: 1025-33.
15. Jung S, Huitinga I, Schmidt B, Zielasek J, Dijkstra CD, Toyka KV, et al. Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis. J Neurol Sci 1993; 119: 195-202.
16. Lassmann H. Comparatative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Berlin: Springer-Verlag; 1983.
17. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 1999; 37: 225-35.
18. Love WG, Amos N, Kellaway IW, Williams BD. Specific accumulation of cholesterol-rich liposomes in the inflammatory tissue of rats with adjuvant arthritis. Ann Rheum Dis 1990; 49: 611-4.
19. Metselaar JM, Wauben MHM, Wagenaar-Hilbers JPA, Boerman OC, Storm G. Joint targeting of glucocorticoids with long-circulating liposomes induces complete remission of experimental arthritis. Arthritis Rheum. In press 2003.
20. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-6.
21. Möllmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res 1995; 12: 1096-100.
22. Morrissey SP, Stodal H, Zettl U, Simonis C, Jung S, Kiefer R, et al. In vivo MRI and its histological correlates in acute adoptive transfer experimental allergic encephalomyelitis. Quantification of inflammation and oedema. Brain 1996; 119: 239-48.
23. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-52.
24. Oku N, Namba Y. Long-circulating liposomes. Crit Rev Ther Drug Carrier Syst 1994; 11: 231-70.
25. Oliveri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998; 50: 1833-6.
26. Rouser G, Fkeischer S, Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 1970; 5: 494-6.
27. Rousseau V, Denizot B, Le Jeune JJ, Jallet P. Early detection of liposome brain localization in rat experimental allergic encephalomyelitis. Exp Brain Res 1999; 125: 255-64.
28. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123: 1431-41.
29. Schmidt J, Sturzebecher S, Toyka KV, Gold R. Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration. J Neurosci Res 2001; 65: 59-67.
30. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113: 171-99.
31. Woodle MC, Newman MS, Cohen JA. Sterically stabilized liposomes: physical and biological properties. J Drug Target 1994; 2: 397-403.
32. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-6.